Abstract accepted for oral presentation at ESOC 2021

The results of a clinical trial carried out as a part of our VIRTUE project will be presented at the 7th European Stroke Organisation Conference (ESOC), 1-3 September, 2021.

Adult patients with a Montreal Cognitive Assessment (MoCA) score below 25 following a stroke, were randomised to receive VR (using VIRTUE) or sham-VR based cognitive rehabilitation therapy along with usual care. Their outcome was assessed at the end of the treatment and at three months using MoCA by a blinded assessor. Participants were interviewed at the end of their treatment for acceptability using a structured questionnaire.

Making a Payment Scenario from Clinical Trial version of software
Figure 1: Making a Payment Scenario from Clinical Trial version of software [PNG]

Forty patients with a MoCA score of 11+8 (mean+SD) were randomised within 10+7 days from their stroke onset. Compared to the controls, those with a severe cognitive impairment (MoCA<15) had a significant improvement in their MoCA score at the end of the treatment, with the VR based cognitive rehabilitation. The VR-based treatment was acceptable to the participants, with only a few adverse reactions reported.

Change in MoCA scores at end of trial
Figure 2: Change in MoCA scores at end of trial [PNG]

Collaborators: Countess of Chester Stroke Unit, Cadscan Ltd. Funding Body: Innovate UK, Innovation in health and life sciences round 2

Reference

  1. Chatterjee, K., John, N. W., Buchanan, A., Hughes, S., Cottrell, K., & Day, T. W. (2021). Virtue: Virtual Reality Based Cognitive Rehabilitation Immediately After a Stroke: A Double-blind Phase 2b Pilot Randomised Controlled Trial. In 7th European Stroke Organisation Conference. [bib]